Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine plus Rituximab vs Fludarabine plus Rituximab in Recurrent Low Grade NHL and MCL
NCT01456351Phase 3Completed
- Sponsor
- Justus Liebig University Giessen
- Start
- Sep 2003
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bendamustine in follicular lymphoma (FL), Lymphoplasmacytic Lymphoma (LPL), marginal zone lymphoma (MZL) and 2 more (2 arms), sponsored by Justus Liebig University Giessen. Primary endpoint: Event Free Survival. Started Sep 2003; status: completed.
02
Drugs
bendamustine
03
Conditions
follicular lymphoma (FL)Lymphoplasmacytic Lymphoma (LPL)marginal zone lymphoma (MZL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01456351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01456351.